Table 1.
Characteristics of patients in the training and validation cohorts
| Characteristic | Training Cohort | Validation Cohort | P-value |
|---|---|---|---|
| Gender, n(%) | 0.570 | ||
| male | 40 (65.6) | 18 (72.0) | |
| female | 21 (34.4) | 7 (28.0) | |
| Age (years) | 0.139 | ||
| Mean | 58.64 | 60.25 | |
| Range | 35–84 | 42–78 | |
| T stage, n(%) | 0.818 | ||
| T1 | 16 (26.2) | 6 (24.0) | |
| T2 | 28 (45.9) | 14 (56.0) | |
| T3 | 7 (11.5) | 1(4.0) | |
| T4 | 10 (16.4) | 4 (16.0) | |
| N stage, n(%) | 0.123 | ||
| N0 | 9(14.8) | 7 (28.0) | |
| N1 | 6 (9.8) | 2 (8.0) | |
| N2 | 19 (31.1) | 9 (36.0) | |
| N3 | 27 (44.3) | 7 (28.0) | |
| M stage, n(%) | 0.576 | ||
| M0 | 35 (57.4) | 16 (64.0) | |
| M1 | 26 (42.6) | 9 (36.0) | |
| Pathological subtype, n(%) | 0.394 | ||
| Adenocarcinoma | 36 (59.0) | 17 (68) | |
| Squamous cell carcinoma | 23 (37.7) | 8 (32) | |
| Large cell lung cancer | 2 (3.3) | 0 (0) | |
| Lymph nodes status, n(%) | 0.885 | ||
| Positive | 99 (60.7) | 42 (61.8) | |
| Negative | 64 (39.3) | 26 (38.2) |